We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?
Read MoreHide Full Article
Key Takeaways
TTD will offer authenticated HCP inventory from OptimizeRx across 400 EHR and e-prescribing systems.
OPRX inventory will reach TTD advertisers via OpenPath in the fourth quarter of 2026.
The integration adds HCP inventory to TTD's healthcare data, measurement and programmatic capabilities.
The Trade Desk (TTD - Free Report) is strengthening its position in the healthcare advertising market through a new integration with OptimizeRx (OPRX - Free Report) , giving advertisers direct access to authenticated healthcare professional (HCP) inventory through TTD’s OpenPath supply-path optimization platform. The initiative gives advertisers using The Trade Desk direct access to OptimizeRx’s authenticated point-of-care inventory across more than 400 electronic health record and e-prescribing systems, reaching approximately 800,000 verified HCPs. The inventory is expected to reach TTD advertisers via OpenPath in the fourth quarter of 2026.
TTD has built a large demand-side platform that allows advertisers and agencies to purchase digital advertising inventory using data-driven targeting and measurement capabilities. OpenPath is designed to improve the connection between advertisers and premium publishers by reducing unnecessary intermediaries in the advertising supply chain. Through The Trade Desk, life sciences advertisers can incorporate OptimizeRx’s point-of-care placements alongside other digital advertising investments. This could simplify media planning and let marketers coordinate HCP-focused campaigns with broader programmatic strategies.
The partnership comes as TTD is expanding its healthcare capabilities in addition to providing media inventory. The company recently announced expanded integrations with Veeva Crossix and IQVIA Digital that allow pharmaceutical advertisers to use more granular healthcare measurement and optimization signals within TTD's platform. The OPRX deal is likely to strengthen TTD’s healthcare offering by adding authenticated HCP inventory, complementing its healthcare data, measurement and programmatic capabilities. This could make TTD more attractive to pharma and life sciences advertisers.
If the integration attracts new pharmaceutical advertisers and encourages existing TTD customers to allocate more of their budgets toward authenticated HCP and point-of-care media, OPRX could become another avenue for TTD to capture a greater share of healthcare programmatic advertising.
How TTD Stacks Up Against Market Peers?
Strong CTV and DV+ demand drive Magnite’s (MGNI - Free Report) growth. It is seeing broader adoption of programmatic advertising, particularly among premium accounts, while international expansion is providing another growth driver as global streamers rely on programmatic channels to reach new markets. Recently, MGNI announced the launch of its first agentic campaign in EMEA with trading desk Amnet France, highlighting how agentic buying can improve the performance and efficiency of premium CTV campaigns. Magnite also expanded partnerships with major global brands, including Walmart, Samsung, Roku, Viasat, AMC and Dentsu, strengthening its CTV and omnichannel capabilities through automated buying, data-driven targeting and broader programmatic access.
PubMatic, Inc.’s (PUBM - Free Report) disciplined investments have diversified its business, with CTV, mobile app and emerging revenues. In the second quarter, CTV, mobile app and emerging streams accounted for about 60% of revenue and grew nearly 40% year over year. CTV revenue rose 13%, led by 25% growth in the Americas, while mobile app revenue jumped more than 40%, driven by mediation integrations, product innovation and a growing global publisher base. Direct buying on Activate more than doubled globally year over year. In June, PUBM launched its first agentic advertising campaign in Spain with Havas and Movistar, marking a key step in European programmatic CTV adoption.
TTD’s Price Performance, Valuation and Estimates
Shares of TTD have declined 71.9% in the past year against the Zacks Internet Services industry and S&P 500 composites’ rise of 34.1% and 17.5%, respectively.
Image Source: Zacks Investment Research
From a valuation standpoint, TTD trades at a forward price-to-earnings of 27.89X, higher than the industry’s average of 21.29X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for TTD’s earnings has been revised downward over the past 60 days.
View the Zacks #1 Rank List
Image: Bigstock
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?
Key Takeaways
The Trade Desk (TTD - Free Report) is strengthening its position in the healthcare advertising market through a new integration with OptimizeRx (OPRX - Free Report) , giving advertisers direct access to authenticated healthcare professional (HCP) inventory through TTD’s OpenPath supply-path optimization platform. The initiative gives advertisers using The Trade Desk direct access to OptimizeRx’s authenticated point-of-care inventory across more than 400 electronic health record and e-prescribing systems, reaching approximately 800,000 verified HCPs. The inventory is expected to reach TTD advertisers via OpenPath in the fourth quarter of 2026.
TTD has built a large demand-side platform that allows advertisers and agencies to purchase digital advertising inventory using data-driven targeting and measurement capabilities. OpenPath is designed to improve the connection between advertisers and premium publishers by reducing unnecessary intermediaries in the advertising supply chain. Through The Trade Desk, life sciences advertisers can incorporate OptimizeRx’s point-of-care placements alongside other digital advertising investments. This could simplify media planning and let marketers coordinate HCP-focused campaigns with broader programmatic strategies.
The partnership comes as TTD is expanding its healthcare capabilities in addition to providing media inventory. The company recently announced expanded integrations with Veeva Crossix and IQVIA Digital that allow pharmaceutical advertisers to use more granular healthcare measurement and optimization signals within TTD's platform. The OPRX deal is likely to strengthen TTD’s healthcare offering by adding authenticated HCP inventory, complementing its healthcare data, measurement and programmatic capabilities. This could make TTD more attractive to pharma and life sciences advertisers.
If the integration attracts new pharmaceutical advertisers and encourages existing TTD customers to allocate more of their budgets toward authenticated HCP and point-of-care media, OPRX could become another avenue for TTD to capture a greater share of healthcare programmatic advertising.
How TTD Stacks Up Against Market Peers?
Strong CTV and DV+ demand drive Magnite’s (MGNI - Free Report) growth. It is seeing broader adoption of programmatic advertising, particularly among premium accounts, while international expansion is providing another growth driver as global streamers rely on programmatic channels to reach new markets. Recently, MGNI announced the launch of its first agentic campaign in EMEA with trading desk Amnet France, highlighting how agentic buying can improve the performance and efficiency of premium CTV campaigns. Magnite also expanded partnerships with major global brands, including Walmart, Samsung, Roku, Viasat, AMC and Dentsu, strengthening its CTV and omnichannel capabilities through automated buying, data-driven targeting and broader programmatic access.
PubMatic, Inc.’s (PUBM - Free Report) disciplined investments have diversified its business, with CTV, mobile app and emerging revenues. In the second quarter, CTV, mobile app and emerging streams accounted for about 60% of revenue and grew nearly 40% year over year. CTV revenue rose 13%, led by 25% growth in the Americas, while mobile app revenue jumped more than 40%, driven by mediation integrations, product innovation and a growing global publisher base. Direct buying on Activate more than doubled globally year over year. In June, PUBM launched its first agentic advertising campaign in Spain with Havas and Movistar, marking a key step in European programmatic CTV adoption.
TTD’s Price Performance, Valuation and Estimates
Shares of TTD have declined 71.9% in the past year against the Zacks Internet Services industry and S&P 500 composites’ rise of 34.1% and 17.5%, respectively.
Image Source: Zacks Investment Research
From a valuation standpoint, TTD trades at a forward price-to-earnings of 27.89X, higher than the industry’s average of 21.29X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for TTD’s earnings has been revised downward over the past 60 days.
Image Source: Zacks Investment Research
TTD currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.